Since drug development is expensive, many pharmaceutical companies have taken measures to speed up development to save time and money. Few of the novel drug candidates that have entered clinical evaluation during the past years have received marketing approval, with safety and efficacy being the major reasons for failure.The importance of biomarkers in improving drug development efficiency has since been emphasized and there has been a surge in the use of complement biomarkers in all phases of complement therapeutic drug development.